Longeveron (LGVN) Share-based Compensation Growth (1y) (2021 - 2026)
Longeveron (LGVN) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -7.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -8.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -22.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 11.71% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -4.01% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -27.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.29% |
| Mar 31, 2026 | 11.47% |
| Dec 31, 2025 | -3.59% |
| Sep 30, 2025 | -68.29% |
| Jun 30, 2025 | 123.04% |
| Mar 31, 2025 | 15.25% |
| Dec 31, 2024 | -5.57% |
| Sep 30, 2024 | 183.17% |
| Jun 30, 2024 | -67.10% |
| Mar 31, 2024 | -29.93% |
| Dec 31, 2023 | -36.07% |
| Sep 30, 2023 | -0.20% |
| Jun 30, 2023 | -22.33% |
| Mar 31, 2023 | -14.26% |
| Dec 31, 2022 | -89.49% |
| Sep 30, 2022 | -79.97% |
| Jun 30, 2022 | -59.44% |
| Mar 31, 2022 | 312.61% |
| Dec 31, 2021 | 204,700.00% |
| Sep 30, 2021 | 19,100.00% |